|
|
|
Insider
Information: |
Akkaraju Srinivas |
Relationship: |
|
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
19 |
|
Direct
Shares |
3,961,226 |
|
Indirect Shares
|
37,470,445 |
|
|
Direct
Value |
$19,952,606 |
|
|
Indirect Value
|
$413,420,042 |
|
|
Total
Shares |
41,431,671 |
|
|
Total
Value |
$433,372,648 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
5
|
3
|
Stock
price went up :
|
4
|
1
|
Stock
price went down : |
1
|
2
|
|
|
|
Gain/Loss Ratio : |
4.0
|
4.0
|
Percentage
Gain/Loss : |
28.4%
|
-84.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Pharmos Corp |
PARS |
Director |
|
0 |
2006-10-25 |
2,845,160 |
Premium* |
|
Seagen Inc |
SGEN |
Director |
2020-05-15 |
41,503 |
2008-09-22 |
600,559 |
Premium* |
|
Paratek Pharmaceuticals Inc |
PRTK |
Former 10% Beneficial ... |
2011-07-19 |
1,181,967 |
|
0 |
Premium* |
|
World Heart Corp |
WHRT |
10% Owner |
2012-08-02 |
0 |
2010-01-26 |
0 |
Premium* |
|
Icagen Inc |
ICGN |
|
2011-07-28 |
200,500 |
|
0 |
Premium* |
|
Synageva BioPharma Corp |
GEVA |
Former Director |
|
0 |
2012-06-27 |
1,026,832 |
Premium* |
|
Durata Therapeutics, Inc. |
DRTX |
10% Owner |
2012-07-24 |
0 |
2012-07-24 |
3,028,439 |
Premium* |
|
MEI Pharma Inc |
MEIP |
10% Owner |
2013-02-19 |
2,502,775 |
|
0 |
Premium* |
|
Zs Pharma, Inc. |
ZSPH |
Director |
2015-12-17 |
0 |
2014-06-23 |
609,455 |
Premium* |
|
aTyr Pharma Inc |
LIFE |
Former 10% Owner, Dire... |
2015-05-12 |
0 |
2015-05-12 |
1,866,126 |
Premium* |
|
Aravive Inc |
ARAV |
Director |
2019-12-02 |
31,815 |
2019-12-02 |
576,066 |
Premium* |
|
Syros Pharmaceuticals, Inc. |
SYRS |
Director |
2023-12-21 |
2,666 |
2023-12-21 |
1,786,427 |
Premium* |
|
Principia Biopharma Inc |
PRNB |
Director |
2018-09-18 |
0 |
2018-09-18 |
383,480 |
Premium* |
|
Chinook Therapeutics Inc |
KDNY |
Director |
2023-08-11 |
0 |
2023-08-11 |
0 |
Premium* |
|
Lenz Therapeutics |
LENZ |
10% Owner |
2021-06-29 |
0 |
2022-04-12 |
8,497,067 |
Premium* |
|
Scholar Rock Holding Corp |
SRRK |
Director, 10% Owner |
|
0 |
2023-10-16 |
6,788,609 |
Premium* |
|
Cargo Therapeutics, Inc. |
CRGX |
10% Owner |
|
0 |
2023-11-14 |
4,121,689 |
Premium* |
|
Mineralys Therapeutics, Inc. |
MLYS |
|
2024-02-12 |
0 |
2024-02-12 |
5,074,916 |
Premium* |
|
Vtv Therapeutics Inc. |
VTVT |
|
2024-02-27 |
0 |
2024-02-27 |
265,620 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
123 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 5
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2020-06-23 |
4 |
AS |
$11.11 |
$565,930 |
I/I |
(50,953) |
1,542,317 |
0 |
% |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2020-06-24 |
4 |
AS |
$11.07 |
$539,788 |
I/I |
(48,775) |
1,493,542 |
0 |
% |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2020-06-25 |
4 |
AS |
$11.15 |
$612,850 |
I/I |
(54,972) |
1,438,570 |
0 |
% |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2020-07-01 |
4 |
AS |
$11.01 |
$50,966 |
I/I |
(4,627) |
1,433,943 |
0 |
% |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2020-08-17 |
4 |
AS |
$13.00 |
$9,672 |
I/I |
(744) |
1,433,199 |
0 |
% |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2020-08-18 |
4 |
AS |
$13.10 |
$2,076,724 |
I/I |
(158,583) |
1,274,616 |
0 |
% |
|
SGEN |
Seagen Inc |
Director |
|
2009-06-25 |
4 |
B |
$9.20 |
$50,633 |
D/D |
5,500 |
5,500 |
2.39 |
- |
|
SGEN |
Seagen Inc |
Director |
|
2009-08-18 |
4 |
B |
$11.47 |
$56,260 |
D/D |
4,905 |
10,405 |
2.39 |
- |
|
WHRT |
World Heart Corp |
10% Owner |
|
2010-01-26 |
4 |
B |
$5.15 |
$2,000,003 |
D/D |
388,350 |
3,721,683 |
2.45 |
- |
|
WHRT |
World Heart Corp |
10% Owner |
|
2010-10-19 |
4 |
B |
$2.14 |
$4,999,999 |
D/D |
2,341,920 |
6,063,603 |
2.45 |
- |
|
DRTX |
Durata Therapeutics, Inc. |
10% Owner |
|
2012-07-24 |
4 |
B |
$9.00 |
$7,058,817 |
I/I |
784,313 |
3,028,439 |
1.5 |
- |
|
LIFE |
aTyr Pharma Inc |
Former 10% Owner |
|
2015-05-12 |
4 |
B |
$14.00 |
$4,480,000 |
I/I |
320,000 |
1,866,126 |
2.1 |
- |
|
ARAV |
Aravive Inc |
Director |
|
2016-10-03 |
4 |
B |
$12.25 |
$7,000,005 |
I/I |
571,429 |
571,429 |
2.1 |
- |
|
ARAV |
Aravive Inc |
Director |
|
2017-03-24 |
4 |
B |
$12.25 |
$7,000,005 |
I/I |
571,429 |
571,429 |
2.1 |
- |
|
ARAV |
Aravive Inc |
Director |
|
2017-12-01 |
4 |
B |
$2.13 |
$893,961 |
I/I |
419,700 |
991,129 |
2.1 |
- |
|
ARAV |
Aravive Inc |
Director |
|
2017-12-04 |
4 |
B |
$2.21 |
$1,135,657 |
I/I |
513,872 |
1,505,001 |
2.1 |
- |
|
ARAV |
Aravive Inc |
Director |
|
2017-12-05 |
4 |
B |
$2.00 |
$85,790 |
I/I |
42,895 |
1,547,896 |
2.1 |
- |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2017-12-12 |
4 |
B |
$9.40 |
$138,876 |
I/I |
14,774 |
735,494 |
2.1 |
- |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2017-12-13 |
4 |
B |
$8.97 |
$613,548 |
I/I |
68,400 |
803,894 |
2.1 |
- |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2017-12-14 |
4 |
B |
$8.99 |
$239,134 |
I/I |
26,600 |
830,494 |
2.1 |
- |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2018-01-31 |
4 |
B |
$9.55 |
$1,999,999 |
I/I |
209,424 |
1,059,938 |
2.1 |
- |
|
ARAV |
Aravive Inc |
Director |
|
2018-06-06 |
4 |
B |
$1.74 |
$1,149,585 |
I/I |
660,681 |
2,234,732 |
2.1 |
- |
|
ARAV |
Aravive Inc |
Director |
|
2018-06-07 |
4 |
B |
$1.85 |
$301,964 |
I/I |
163,224 |
2,397,956 |
2.1 |
- |
|
ARAV |
Aravive Inc |
Director |
|
2018-06-08 |
4 |
B |
$2.00 |
$463,160 |
I/I |
231,580 |
2,629,536 |
2.1 |
- |
|
ARAV |
Aravive Inc |
Director |
|
2018-06-13 |
4 |
B |
$2.13 |
$112,928 |
I/I |
53,018 |
2,682,554 |
2.1 |
- |
|
123 Records found
|
|
Page 2 of 5 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|